(E)-3-(4-(4,4-difluorocyclohexyloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)acrylamide

ID: ALA3912681

Chembl Id: CHEMBL3912681

PubChem CID: 73051907

Max Phase: Preclinical

Molecular Formula: C15H16F2N4O2

Molecular Weight: 322.32

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  NC(=O)/C=C/c1c[nH]c2ncnc(OC3CCC(F)(F)CC3)c12

Standard InChI:  InChI=1S/C15H16F2N4O2/c16-15(17)5-3-10(4-6-15)23-14-12-9(1-2-11(18)22)7-19-13(12)20-8-21-14/h1-2,7-8,10H,3-6H2,(H2,18,22)(H,19,20,21)/b2-1+

Standard InChI Key:  IIBQLYSZHMEQIH-OWOJBTEDSA-N

Alternative Forms

1. Parent:

   

   ALA3912681

   (E)-3-[4-(4,4-difluorocyclohexyl)oxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl]prop-2-enamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 322.32

Molecular Weight (Monoisotopic): 322.1241

AlogP: 2.41

#Rotatable Bonds: 4

Polar Surface Area: 93.89

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.68

CX Basic pKa: 5.00

CX LogP: 1.59

CX LogD: 1.59

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.85

Np Likeness Score: -0.08

References

1.  (2014)  4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment, 

2.  (2016)  4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment, 

Source

Source(2):

• BindingDB Database
• Patent Bioactivity Data